Market Cap : 134.19 B | Enterprise Value : 162.91 B | PE Ratio : 21.29 | PB Ratio : 55.56 |
---|
NAS:AMGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:AMGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Amgen's Cash Ratio for the quarter that ended in Jun. 2022 was 0.57.
Amgen has a Cash Ratio of 0.57. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Amgen's Cash Ratio or its related term are showing as below:
During the past 13 years, Amgen's highest Cash Ratio was 18.80. The lowest was 0.09. And the median was 1.51.
AMGN's Cash Ratio is ranked worse thanThe historical data trend for Amgen's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amgen's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Amgen's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Amgen's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Ratio (A: Dec. 2021 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 8037 | / | 12184 | |
= | 0.66 |
Amgen's Cash Ratio for the quarter that ended in Jun. 2022 is calculated as:
Cash Ratio (Q: Jun. 2022 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 7183 | / | 12618 | |
= | 0.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Amgen's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Miller Derek | officer: SVP, Human Resources | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Khosla Rachna | officer: SVP, Business Development | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Ishrak Omar | director | 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Louie Linda H. | officer: VP, Finance & CAO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Miles Amy E | director | |
Grygiel Nancy A. | officer: SVP & CCO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Griffith Peter H. | officer: EVP & CFO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Gordon Murdo | officer: EVP Global Commercial Ops | C/O BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVE NEW YORK NY 10154 |
Reese David M | officer: EVP, Research and Development | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Druker Brian | director | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
Austin Wanda M | director | 6001 BOLLINGER CANYON ROAD SAN RAMON CA 94583 |
Holley Charles M | director | |
Johnston Lori A | officer: SVP, HR | C/O AMGEN INC. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Kullman Ellen Jamison | director | UNITED TECHNOLOGIES CORP 10 FARM SPRINGS ROAD FARMINGTON CT 06032 |
Santos Esteban | officer: EVP, Operations | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
From GuruFocus
By PRNewswire 02-16-2022
By PRNewswire 02-03-2022
Other Sources
By Zacks 2022-03-22
By Zacks 2022-03-07
By Zacks 2022-03-02
By tipranks.com 2022-02-28
By Zacks 2022-03-21
By Fool 2022-04-01
By Zacks 2022-03-21
By Zacks 2022-03-23
By Zacks 2022-04-04
By Zacks 2022-03-28
By Zacks 2022-03-09
By Zacks 2022-02-25
By Zacks 2022-03-24